Literature DB >> 24706856

Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice.

Andrew J Murphy1, Lynn E Macdonald, Sean Stevens, Margaret Karow, Anthony T Dore, Kevin Pobursky, Tammy T Huang, William T Poueymirou, Lakeisha Esau, Melissa Meola, Warren Mikulka, Pamela Krueger, Jeanette Fairhurst, David M Valenzuela, Nicholas Papadopoulos, George D Yancopoulos.   

Abstract

Mice genetically engineered to be humanized for their Ig genes allow for human antibody responses within a mouse background (HumAb mice), providing a valuable platform for the generation of fully human therapeutic antibodies. Unfortunately, existing HumAb mice do not have fully functional immune systems, perhaps because of the manner in which their genetic humanization was carried out. Heretofore, HumAb mice have been generated by disrupting the endogenous mouse Ig genes and simultaneously introducing human Ig transgenes at a different and random location; KO-plus-transgenic humanization. As we describe in the companion paper, we attempted to make mice that more efficiently use human variable region segments in their humoral responses by precisely replacing 6 Mb of mouse Ig heavy and kappa light variable region germ-line gene segments with their human counterparts while leaving the mouse constant regions intact, using a unique in situ humanization approach. We reasoned the introduced human variable region gene segments would function indistinguishably in their new genetic location, whereas the retained mouse constant regions would allow for optimal interactions and selection of the resulting antibodies within the mouse environment. We show that these mice, termed VelocImmune mice because they were generated using VelociGene technology, efficiently produce human:mouse hybrid antibodies (that are rapidly convertible to fully human antibodies) and have fully functional humoral immune systems indistinguishable from those of WT mice. The efficiency of the VelocImmune approach is confirmed by the rapid progression of 10 different fully human antibodies into human clinical trials.

Entities:  

Keywords:  antibody generation; immunoglobulin loci

Mesh:

Year:  2014        PMID: 24706856      PMCID: PMC3986188          DOI: 10.1073/pnas.1324022111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

Review 1.  Factors that influence formation of B cell repertoire.

Authors:  A J Feeney
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  Subnuclear compartmentalization of immunoglobulin loci during lymphocyte development.

Authors:  Steven T Kosak; Jane A Skok; Kay L Medina; Roy Riblet; Michelle M Le Beau; Amanda G Fisher; Harinder Singh
Journal:  Science       Date:  2002-04-05       Impact factor: 47.728

3.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

Review 4.  IgG Fc receptors.

Authors:  J V Ravetch; S Bolland
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

5.  Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice.

Authors:  M J Mendez; L L Green; J R Corvalan; X C Jia; C E Maynard-Currie; X D Yang; M L Gallo; D M Louie; D V Lee; K L Erickson; J Luna; C M Roy; H Abderrahim; F Kirschenbaum; M Noguchi; D H Smith; A Fukushima; J F Hales; S Klapholz; M H Finer; C G Davis; K M Zsebo; A Jakobovits
Journal:  Nat Genet       Date:  1997-02       Impact factor: 38.330

6.  Maturation of the immune response in germinal centers.

Authors:  C Berek; A Berger; M Apel
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

7.  Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in mu and gamma transcripts.

Authors:  N Tuaillon; L D Taylor; N Lonberg; P W Tucker; J D Capra
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

8.  B cell receptor signal strength determines B cell fate.

Authors:  Stefano Casola; Kevin L Otipoby; Marat Alimzhanov; Sibille Humme; Nathalie Uyttersprot; Jeffery L Kutok; Michael C Carroll; Klaus Rajewsky
Journal:  Nat Immunol       Date:  2004-02-01       Impact factor: 25.606

Review 9.  Large-scale chromatin remodeling at the immunoglobulin heavy chain locus: a paradigm for multigene regulation.

Authors:  Daniel J Bolland; Andrew L Wood; Anne E Corcoran
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

10.  The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus.

Authors:  F Matsuda; K Ishii; P Bourvagnet; K i Kuma; H Hayashida; T Miyata; T Honjo
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more
  110 in total

1.  Reply to Dimitrov et al.: VelociSuite technologies are a foundation for rapid therapeutic antibody development.

Authors:  Christos A Kyratsous; William Olson; Neil Stahl
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-28       Impact factor: 11.205

Review 2.  The present state of the art in expression, production and characterization of monoclonal antibodies.

Authors:  Christopher L Gaughan
Journal:  Mol Divers       Date:  2015-08-25       Impact factor: 2.943

3.  Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition.

Authors:  Haruka Okamoto; Katie Cavino; Erqian Na; Elizabeth Krumm; Steven Kim; Panayiotis E Stevis; Joyce Harp; Andrew J Murphy; George D Yancopoulos; Jesper Gromada
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-31       Impact factor: 11.205

4.  AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.

Authors:  Daniel S Pereira; Claudia I Guevara; Liqing Jin; Nathan Mbong; Alla Verlinsky; Ssucheng J Hsu; Hector Aviña; Sher Karki; Joseph D Abad; Peng Yang; Sung-Ju Moon; Faisal Malik; Michael Y Choi; Zili An; Kendall Morrison; Pia M Challita-Eid; Fernando Doñate; Ingrid B J Joseph; Thomas J Kipps; John E Dick; David R Stover
Journal:  Mol Cancer Ther       Date:  2015-05-01       Impact factor: 6.261

5.  A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant.

Authors:  Shauna L French; Claudia Thalmann; Paul F Bray; Lynn E Macdonald; Andrew J Murphy; Mark W Sleeman; Justin R Hamilton
Journal:  Blood Adv       Date:  2018-06-12

6.  Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties.

Authors:  Lynn E Macdonald; Karoline A Meagher; Matthew C Franklin; Natasha Levenkova; Johanna Hansen; Ashok T Badithe; Maggie Zhong; Pamela Krueger; Ashique Rafique; Naxin Tu; James Shevchuk; Saurabh Wadhwa; George Ehrlich; Joannie Bautista; Craig Grant; Lakeisha Esau; William T Poueymirou; Wojtek Auerbach; Lori Morton; Robert Babb; Gang Chen; Tammy Huang; Douglas MacDonald; Kenneth Graham; Cagan Gurer; Vera A Voronina; John R McWhirter; Chunguang Guo; George D Yancopoulos; Andrew J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-26       Impact factor: 11.205

Review 7.  Combinations of chromosome transfer and genome editing for the development of cell/animal models of human disease and humanized animal models.

Authors:  Narumi Uno; Satoshi Abe; Mitsuo Oshimura; Yasuhiro Kazuki
Journal:  J Hum Genet       Date:  2017-11-27       Impact factor: 3.172

Review 8.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; William C Olson; Fiona H Marshall
Journal:  Nat Rev Drug Discov       Date:  2017-07-14       Impact factor: 84.694

9.  Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes.

Authors:  Christine J Rossant; Danielle Carroll; Ling Huang; John Elvin; Frances Neal; Edward Walker; Joris J Benschop; Eldar E Kim; Simon T Barry; Tristan J Vaughan
Journal:  MAbs       Date:  2014       Impact factor: 5.857

10.  Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.

Authors:  Kristen E Pascal; Christopher M Coleman; Alejandro O Mujica; Vishal Kamat; Ashok Badithe; Jeanette Fairhurst; Charleen Hunt; John Strein; Alexander Berrebi; Jeanne M Sisk; Krystal L Matthews; Robert Babb; Gang Chen; Ka-Man V Lai; Tammy T Huang; William Olson; George D Yancopoulos; Neil Stahl; Matthew B Frieman; Christos A Kyratsous
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.